Ardaman Shergill

机构：University of Chicago, University of Chicago Medical Center · ORCID：0000-0003-0675-7760

发表论文 136 篇 · 总被引 4261 次 · h-index 22

代表论文

• Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). (2025 · Journal of Clinical Oncology · 被引 53)
• Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib (2025 · JAMA Oncology · 被引 9)
• Defining a ‘cells to society’ research framework for appendiceal tumours (2025 · Nature reviews. Cancer · 被引 9)
• Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. (2025 · Journal of Clinical Oncology · 被引 9)
• Utilizing Patient Input in Rectal Cancer Trial Design (2025 · JNCI Journal of the National Cancer Institute · 被引 4)
• Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602). (2025 · Journal of Clinical Oncology · 被引 4)